Agenus Inc (AGEN)

[dia76ca]

The Facts About PD-1 according to Feb.25 newsletter. Most of the newsletter explains the innovative BEST financing method.

• Commercial opportunity for our PD-1 in 2L cervical cancer represents up to ~$300M in estimated annual US sales for Agenus
• Commercial opportunity in expanded indications and/or combinations1 represent up to ~$1.5-2Bn in potential annual US sales
for Agenus
• Our PD-1 (AGEN2034) is on track for a BLA filing in 2020 for treatment of 2nd line cervical cancer
• Agenus’ operating plans for approval in cervical cancer are supported by our current budget; Exploiting the market beyond
cervical cancer will require additional investment

• All PD-1 antibodies that have entered late-stage clinical development have been approved; our PD-1 is in late stage development
• Combinations with PD-1 have shown improved benefit for patients - the field is moving to PD-1 combinations
• Agenus’ deep pipeline enables optimal combinations with our PD-1, including combinations with our next generation CTLA-4
• The large and growing market for approved PD-1s is estimated at ~$20B in 2019